We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ocular Disease Genes Identified by Screening Multiple Genomes

By LabMedica International staff writers
Posted on 08 Jan 2019
Print article
Image: New research marks a crucial step forward in the effort to identify the cause of impaired vision in people around the world. Eyesight problems frequently have a genetic origin, and often a mutation in just a single gene is involved. However, the genetic contribution of many eye-related issues remains poorly understood (Photo courtesy of the IMPC).
Image: New research marks a crucial step forward in the effort to identify the cause of impaired vision in people around the world. Eyesight problems frequently have a genetic origin, and often a mutation in just a single gene is involved. However, the genetic contribution of many eye-related issues remains poorly understood (Photo courtesy of the IMPC).
Results obtained during the genetic screening of a large number of mice revealed 347 genes that influenced ocular phenotypes, 75% of which were not previously known to be linked to ocular disease.

These ophthalmic findings from a study conducted under the auspices of the International Mouse Phenotyping Consortium (IMPC) were reported in the December 21, 2018, online edition of the journal Nature Communications Biology.

The IMPC is an international scientific project designed to create and characterize the phenotype of 20,000 knockout mouse strains. Launched in September 2011, the consortium comprises more than 15 research institutes across four continents with funding provided by the [U.S.] National Institutes of Health, European national governments, and the partner institutions.

In the current study, 4364 genes were evaluated and 347 were identified to influence ocular phenotypes, 75% of which are entirely novel in ocular pathology. This discovery greatly increased the current number of genes known to contribute to ophthalmic disease.

"This is extremely valuable for people with hereditary eye disease," said senior author Dr. Ala Moshiri, assistant professor of vitreoretinal surgery and uveitis at the University of California, Davis (USA). "The whole ophthalmic community is going to start using these data."

"In 2018, if someone has a form of hereditary blindness, we can identify the cause 50 to 75% of the time," said Dr. Moshiri. "In the remaining cases, we know the mutation is there but we do not know where to look. Now eye centers that do DNA sequencing can call back patients and screen them for these new genes."

Related Links:
International Mouse Phenotyping Consortium
University of California, Davis

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.